Galapagos Acquires Drug Discovery Services Business | GenomeWeb

NEW YORK (GenomeWeb News) – Belgian drug discovery and development firm Galapagos today announced that it has acquired the service operations of Argenta Discovery for €16.5 million ($23 million).

The privately held contract drug discovery business employs 140 and is based in the UK. Its respiratory drug development business, called Pulmagen Therapeutics, will operate as a new privately held firm, in which Galapagos will have no ownership.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The White House has created a list of cuts, including to the NIH, that could be in a budget bill for this year.

The US National Institutes of Health is to allow applicants to cite preprints just as they would any other research paper, ScienceInsider reports.

Two manuscript pages handwritten by Charles Darwin are going on the auction block, according to the Los Angeles Times.

In PNAS this week: tool to track transcriptome-wide binding, evidence of balancing selection on behavior-linked genes, and more.